🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. a benzodiazepine drug

    Jazz Pharmaceuticals Ireland Limited

    Anxiety Disorder

    phase 3 small molecule completed

    1 trial

  2. albuterol (Armstrong Albuterol HFA)

    Amphastar France Pharmaceuticals

    Asthma

    phase 3 small molecule terminated

    1 trial

  3. albuterol HFA (Armstrong's)

    Amphastar France Pharmaceuticals

    Asthma

    phase 3 small molecule terminated

    1 trial

  4. albuterol aerosol by HFA MDI

    Teva Pharma GmbH

    Exercise-induced Bronchospasm

    phase 3 small molecule completed

    1 trial

  5. alprazolam, Placebo matching Staccato® alprazolam and without active substance

    Lacuna Pharma Pty Ltd

    Treatment of stereotypical prolonged seizure

    phase 3 small molecule active

    1 trial

  6. amifampridine phosphate

    CATALYST PHARMACEUTICALS, INC.

    Myasthenic Syndromes, Congenital

    phase 3 small molecule completed

    1 trial

  7. ampreloxetine

    Theravance Biopharma Ireland Umited

    Symptomatic Neurogenic Orthostatic Hypotension

    phase 3 small molecule active

    4 trials

  8. apomorphine infusion

    SUPERNUS PHARMACEUTICALS, INC.

    Idiopathic Parkinson's Disease

    phase 3 small molecule active

    1 trial

  9. beclomethasone dipropionate (QVAR)

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule completed

    1 trial

  10. bendamustine

    Teva Pharma GmbH

    Non-Hodgkin's Lymphoma

    phase 3 small molecule completed

    2 trials

  11. bimatoprost ophthalmic solution formulation A

    Allergan Pharmaceuticals International Limited

    Glaucoma

    phase 3 small molecule terminated

    1 trial

  12. bimekizumab

    Lacuna Pharma Pty Ltd

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  13. bimekizumab

    Lacuna Pharma Pty Ltd

    Active juvenile idiopathic arthritis subtypes enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritis

    phase 3 small molecule active

    1 trial

  14. bimekizumab

    Lacuna Pharma Pty Ltd

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  15. bimekizumab

    Lacuna Pharma Pty Ltd

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  16. bimekizumab

    Lacuna Pharma Pty Ltd

    Axial Spondyloarthritis

    phase 3 small molecule active

    1 trial

  17. bimekizumab, Skyrizi 150 mg solution for injection in pre-filled syringe, Placebo matching test and comparator. 0.9% sodium chloride solution for injection (unauthorized).

    Lacuna Pharma Pty Ltd

    Psoriatic arthritis

    phase 3 small molecule active

    1 trial

  18. blisibimod

    Santhera Pharmaceuticals (Deutschland) GmbH

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    1 trial

  19. botulinum toxin Type A

    Allergan Pharmaceuticals International Limited

    Pediatrics

    phase 3 mab completed

    4 trials

  20. brivaracetam, -, -, brivaracetam, -, brivaracetam, Placebo matching < brivaracetam oral solution> and without active substance

    Lacuna Pharma Pty Ltd

    Childhood Absence Epilepsy Juvenile Absence Epilepsy

    phase 3 small molecule active

    1 trial

  21. brivaracetam, brivaracetam, brivaracetam, brivaracetam

    Lacuna Pharma Pty Ltd

    Childhood Absence Epilepsy, Juvenile Absence Epilepsy

    phase 3 small molecule active

    1 trial

  22. canakinumab

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 3 small molecule terminated

    2 trials

  23. centrally blinded product containing all the same manufactured ingredients and excipients as the DM199 formulation, except for the active pharmaceutical ingredient (API).

    DiaMedica Therapeutics

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  24. cisplatin

    Pari Pharma GmbH

    Lung Cancer

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources